First, the methods behind the WHO Priority Pathogens List (PPL, released on 25 Feb 2017) have now been published by Tacconelli et al. in Lancet Infectious Diseases along with an editorial by Tillottson. As further context while you review these excellent papers, you might also find it helpful to have to hand this slide deck comparing the WHO PPL, the 2013 CDC threat list, and the 2008-9 ESKAPE pathogen list.
You should read the papers yourself, but the quick summary is that the authors used multicriteria decision analysis across 10 axes (mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline) to prioritize the pathogens. Very importantly, they obtained input from 70 experts spanning all 6 WHO regions, thus ensuring a broad view on global needs.
Second, there has been a lot of action underway to address the gaps identified by the WHO PPL and the related WHO pipeline review from this past summer. I am seeing significant amounts of company-level activity and one measure of this is that CARB-X now lists 22 projects in its portfolio page. As an additional perspective on recent actions at the Industry level, I've learned that the AMR Industry Alliance will release its first Global Progress report on 18 Jan 2018 in Geneva. You can register to attend that meeting via this link. This is all very exciting to see!
In closing, all best wishes for the holidays and thank you for being one of the just over 1,000 subscribers to this newsletter! I've enjoyed writing these occasional updates and I've also appreciated all the helpful comments and tips that I've received.
Ho, ho, ho! --jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog-index.html
Upcoming meetings of interest to the AMR community: